SIX2 Mediates Late-Stage Metastasis Via Direct Regulation of and Induction of a Cancer Stem Cell Program
Overview
Authors
Affiliations
The capacity for tumor cells to metastasize efficiently is directly linked to their ability to colonize secondary sites. Here we identify Six2, a developmental transcription factor, as a critical regulator of a breast cancer stem cell program that enables metastatic colonization. In several triple-negative breast cancer (TNBC) models, Six2 enhanced the expression of genes associated with embryonic stem cell programs. Six2 directly bound the Srr2 enhancer, promoting expression and downstream expression of , which are both key pluripotency factors. Regulation of by Six2 enhanced cancer stem cell properties and increased metastatic colonization. and expression correlated highly in breast cancers including TNBC, where a Six2 expression signature was predictive of metastatic burden and poor clinical outcome. Our findings demonstrate that a SIX2/SOX2 axis is required for efficient metastatic colonization, underscoring a key role for stemness factors in outgrowth at secondary sites. SIGNIFICANCE: These findings provide novel mechanistic insight into stemness and the metastatic outgrowth of triple-negative breast cancer cells. http://cancerres.aacrjournals.org/content/canres/79/4/720/F1.large.jpg.
Liu W, Luo G Transl Oncol. 2024; 50():102149.
PMID: 39395272 PMC: 11736403. DOI: 10.1016/j.tranon.2024.102149.
Chen R, Tang L, Melendy T, Yang L, Goodison S, Sun Y Cancer Res Commun. 2024; 4(10):2783-2798.
PMID: 39347576 PMC: 11500312. DOI: 10.1158/2767-9764.CRC-24-0210.
Zhang Z, Huang H, Peng L, Zhou B, Yang H, Tang Z Int J Biol Sci. 2024; 20(12):4618-4634.
PMID: 39309424 PMC: 11414381. DOI: 10.7150/ijbs.93411.
Wang B, Wang Y, Wang W, Wang Z, Zhang Y, Pan X J Exp Clin Cancer Res. 2024; 43(1):204.
PMID: 39044249 PMC: 11264439. DOI: 10.1186/s13046-024-03120-w.
All eyes on Eya: A unique transcriptional co-activator and phosphatase in cancer.
Hughes C, Alderman C, Wolin A, Fields K, Zhao R, Ford H Biochim Biophys Acta Rev Cancer. 2024; 1879(3):189098.
PMID: 38555001 PMC: 11111358. DOI: 10.1016/j.bbcan.2024.189098.